00:00We have pharmaceutical, packaging, pesticides, engineering unit and color in 90 liter.
00:29We know that in the last month, the Trump tariff was exported.
00:49We have exported all 10 units in the temple.
00:53and the industry has been exported in a very long time.
01:02There was a tax tax tax, and a tax tax tax tax.
01:06We have made a deal with S.S.S.R.S.R.A.P.A.N.R.M.M.H.I.S.H.A.V.
01:13and Donald Trump.
01:16The deal is that we have to export and export it to our country, especially in pharmaceuticals.
01:26We have to get a lot of money, and we have to get a lot of money, and we have to get a lot of money.
01:36The deal is that we have to get a lot of money, and we have to get a lot of money.
01:43but the first thing is that the government was working on the first 3rd budget,
01:48and that was the first thing.
01:50So, that deal is important,
01:53even though the government's government has been working on the company industry,
01:59and the first thing was that the U-deal was the 17th European country,
02:06The impact of the impact on our level is that the government has been affected by the government.
02:19The government has been affected by the market.
02:22The American market has not been announced, but the market has been affected by the new market.
02:27It is important that there is a vaccine, a vaccine, and there is a lot of tariff in our country.
02:36Today, the tariff has been adapted, and we have been able to do it.
02:41There is a lot of feedback in our work.
02:45There is also a lot of feedback that we have been able to do it.
02:48We have been able to do it for 6 months, and we have been able to do it for 3 tariff.
02:56There is also a chemical, pharmaceutical, textile hub.
03:01There is also a lot of MSME industries.
03:05Overall, there is a lot of time when the trade deal has been made before we have been able to keep tariffs.
03:16So, we have been able to keep the industries a lot of orders in our country.
03:22The second thing is that the production capacity has increased.
03:25It has been affected by the turnover, the production capacity.
03:31Thanks to Prime Minister Narendra Modi and his team,
03:37we have been able to do the decision quickly and that there is a lot of good options.
03:42Because there is a tariff in 24 countries, not in 24 countries, there is a tariff in our example of the textile market.
03:54In the textile market, Bangladesh has one hub in the US, but in Bangladesh, there is uncertainty in the US, and there is a tariff in the US.
04:04The business sector has a benefit from the textile sector.
04:09The second thing, the pharmaceutical, the generic drugs, there is almost 47% of the US consumption.
04:16There are many industries in the US, and there is also a raw material that has a pharmaceutical hub.
04:28There is also a supply of raw materials.
04:31But against raw materials, there is also a lot of products that have been supplied by Hyderabad, and there is also a final drug.
04:38This business has been in the same line.
04:41The second option is that against India's competition.
04:47The second option is that in India's phase, we have struggled with India and China.
04:51However, the tariff has lost two options.
04:54The US citizens have lost two options.
04:56So I thought that they always have a preference for India.
05:00So the Indian market has a preference for India.
05:02So we have a lot of tariff in China.
05:05The first choice is that in the first choice, pharma sector has also been able to get a problem.
05:11Overall, the impact of our GDP will be able to get 0.2 to 0.5% to 0.5%.
05:17And business expansions and R&D will be able to be beneficial.
05:21My name is Dr. Kamal Oshri.
05:24I have been working as a president in Bangladesh.
05:26And I am a manufacturer of the pharmaceuticals API.
05:31See, we have talked about the US tariffs and the EU deal.
05:35The deal is the most important.
05:38So we have a global gateway to the Indian pharmaceutical industry.
05:43That deal together.
05:45And in the US, we have a lot of tariff and geopolitical situations in Europe.
05:52The pharma industry is very difficult.
05:54And in the US, we have MSME industries.
05:57Small-skills.
05:58So everyone is so difficult.
06:00Because the main business is in the pharmaceutical industry.
06:03The majority of the US is in Europe.
06:07That deal is in the harmonized way.
06:11There is a big advantage of long-term contracts.
06:14The industry has been clear.
06:27So the firm will have new employees.
06:29New investments.
06:31And we can pay attention to the customers.
06:33And the most important thing is,
06:35that we have a policy in the world.
06:38So we don't have to use pharmaceuticals.
06:40Now we don't have to use it.
06:41So, in China, India is a big deal.
06:44So, anyway, we are now becoming a global leader.
06:47And in pharmaceutical, there are a lot of people who are becoming a big deal.
06:51Especially in the API.
06:52So, we are going to make our product in China.
06:58So, we are going to make our product in every product.
07:03So, we are going to make our product competitive price.
07:05We are going to make our business growth very well.
07:08In Wapi, there are many companies that are exported to the global level.
07:13And not just Europe, US, but also Africa.
07:17And in numbers, it is a little difficult.
07:20But in Wapi, there is also a lot of pharma industry in Wapi.
07:24There are also a lot of chemical industries.
07:25There are also a lot of dyes industries.
07:26There are also a lot of Europe and US markets.
07:28And there are also a lot of export.
07:30So, we are going to have 1000 units in Wapi GIDC.
07:34When we have a chemical industry, we are going to have 50% of this.
07:37So, most of the people of all, aren't very much so far,
07:41Who are at all, are not very used.
07:42They are going to get to export.
07:44So, everyone will have very valuable results.
07:46Over the next weeks, we will have seen an interview.
07:48In this week, everyone will have a great support for itself.
07:49I will have a huge thanks to viewership.
07:54And, within 2020, I really appreciate the work that we do in this week.
Comments